Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Whole Blood Clotting Time Clear all
Completed No phase listed Observational Accepts healthy volunteers

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

NCT00096590
View directory record Official record
Conditions
Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
coagulation study, immunoenzyme technique, laboratory biomarker analysis, physiologic testing, study of high risk factors
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2009 · Synced Sep 24, 2026, 8:20 AM EDT
Not listed No phase listed Observational

Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery

NCT04785885
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement, Cardiac Valve Annuloplasty
Interventions
iStat Handheld Blood Analyzer, Hemochron
Diagnostic Test
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture

NCT02207205
View directory record Official record
Conditions
Healthy
Interventions
Blood drawn from indwelling catheters versus direct venipuncture
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

NCT02205827
View directory record Official record
Conditions
Healthy
Interventions
Single-arm
Other
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

NCT02206100
View directory record Official record
Conditions
Healthy
Interventions
PER977, Placebo, enoxaparin
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

NCT03288454
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Apixaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 24, 2026, 8:20 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

NCT05147662
View directory record Official record
Conditions
Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions
Damoctocog alfa pegol (Jivi, BAY94-9027)
Biological
Lead sponsor
Bayer
Industry
Eligibility
7 Years to 11 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed No phase listed Observational

QStat Cartridge in Obstetric Patients

NCT06255496
View directory record Official record
Conditions
Blood Loss Massive, Post Partum Hemorrhage
Interventions
Quantra Hemostasis Analyzer with the QStat Cartridge
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Rochester, New York • Columbus, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects

NCT03157518
View directory record Official record
Conditions
Asthma
Interventions
Seeking Health Probiota Bifido
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 24, 2026, 8:20 AM EDT
Recruiting No phase listed Observational

Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™

NCT07012291
View directory record Official record
Conditions
Coagulation
Interventions
Whole Blood Clotting Time
Device
Lead sponsor
Perosphere Technologies Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 24, 2026, 8:20 AM EDT
Completed No phase listed Observational

Trauma Induced Coagulopathy and Inflammation

NCT03128658
View directory record Official record
Conditions
Trauma Injury, Trauma, Coagulopathy
Interventions
Thromboelastography, Computational model
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
View directory record Official record
Conditions
Breast Cancer Prevention, Mammographic Density
Interventions
Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Completed No phase listed Observational Results available

In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.

NCT00788255
View directory record Official record
Conditions
Anesthesia
Interventions
Final exogenous oxytocin concentration=22.5 μU/mL, Final exogenous oxytocin concentration=30.1μU/mL, Final exogenous oxytocin concentration=32.9μU/mL
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 24, 2026, 8:20 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Withdrawn Not applicable Interventional

Thromboelastography to Study Burn Coagulopathy

NCT06879509
View directory record Official record
Conditions
Burn, Coagulation, Blood
Interventions
Thromboelastography
Diagnostic Test
Lead sponsor
Francesco Egro
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

NCT03372109
View directory record Official record
Conditions
Body Weight Changes
Interventions
Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 24, 2026, 8:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947
View directory record Official record
Conditions
Frail Elderly, Coronary Artery Disease
Interventions
Off-pump coronary-artery bypass grafting, On-pump coronary-artery bypass grafting
Other
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
60 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 24, 2026, 8:20 AM EDT
Recruiting No phase listed Observational

Pharmacogenomics of Warfarin in Hispanics and Latinos

NCT02972385
View directory record Official record
Conditions
Thrombosis, Hemorrhage
Interventions
Mouthwash sample, Blood Draw
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 24, 2026, 8:20 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

NCT02557672
View directory record Official record
Conditions
Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions
Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP)
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 24, 2026, 8:20 AM EDT
Completed No phase listed Observational

Quantra QPlus Sample Type Comparison

NCT05290675
View directory record Official record
Conditions
Coagulation Defect; Bleeding
Interventions
Quantra QPlus System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 24, 2026, 8:20 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

NCT04917965
View directory record Official record
Conditions
Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions
Laboratory clotting studies
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
0 Hours to 2 Hours
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 24, 2026, 8:20 AM EDT